JenaValve Technology Welcomes Jane Metcalf as Vice President, Regulatory Affairs and Quality
IRVINE, Calif. -- JenaValve Technology, Inc., developer and manufacturer of differentiated pericardial transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, announces the appointment of Jane Metcalf toVice President, Regulatory Affairs and Quality, effective immediately. Ms. Metcalf comes to JenaValve with over 30 years of experience in themedical device industry providing leadership in areas of regulatory affairs, clinical and quality assurance.
“Jane has a strong track record of successfully developing strategies for worldwide regulatory approvals of innovative devices,” saidJenaValve CEO John Kilcoyne. “I am excited Jane is joining us at this pivotal time as we continue to enroll patients into our ALIGN-ARclinical trial and move forward in our efforts to commercialize our TrilogyTM heart valve for the treatment of aortic regurgitation. Herleadership will be critical to the success of JenaValve and our ability to expand patient and physician awareness.”
Prior to joining JenaValve, Ms. Metcalf served as Vice President of Regulatory Affairs and Quality Assurance at Sonendo Medical. Previously, she held senior leadership positions at emerging growth companies, including Interventional Spine, Rebound Therapeutics and Viseon Spine.Ms. Metcalf received a B.S. degree in chemical engineering from the University of Massachusetts, Amherst and an MBA from the University ofCalifornia, Irvine.
JenaValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA), which allows for priority review of the ALIGN Clinical Trial for the treatment of symptomatic, severe aortic regurgitation (AR) and AR-dominant mixed aortic valve disease.JenaValve’s TAVR System is differentiated in that no other transcatheter valve device is currently available for patients suffering from severe aortic regurgitation who are at high risk for open heart surgery. Following completion of the HDE portion of the trial, patient enrollment is expected to continue in support of a Premarket Approval (PMA) application to the FDA. The company is also pursuing CE mark approval forboth aortic stenosis and aortic regurgitation.
About the JenaValve Transfemoral TAVR System
The JenaValve Pericardial TAVR System consists of a Pericardial Aortic Valve and Transfemoral Delivery System. The bioprosthesis comprises a self-expanding nitinol stent with a porcine pericardial valve manufactured using state-of-the-art tissue processing techniques. The transfemoraldelivery catheter is designed to deliver the bioprosthesis using a simple stepped approach with anatomic positioning over the native valve. The System is available in three sizes intended for aortic annulus diameters from 21mm to 27mm.
The JenaValve Pericardial TAVR System is an investigational device in the United States and internationally.
About JenaValve
JenaValve Technology, Inc., with locations in Irvine, California, Leeds, U.K. and Munich, Germany, develops and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from aortic valve disease. The Company is in clinical development of its next generation transfemoral TAVR system in both the U.S. and CE mark countries for treating patients with aortic stenosis and/or aortic regurgitation.
JenaValve is backed by Bain Capital Life Sciences as well as European and Asian investors, including Andera Partners (formerly Edmond deRothschild Investment Partners), Gimv (Euronext: GIMB), Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners.
Additional information is available at www.jenavalve.com.
Related news
-
Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow Mini Flusher Device for Hydrocephalus Patients
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce the successful first implant of the Company’s...
-
7-year-old Boy Managing His Hydrocephalus with ReFlow Ventricular System “Gen 1” Featured on Charleston’s ABC News 4
After struggling to conceive a child for what felt like ages, Miranda of Moncks County, South Carolina finally fell pregnant - a miracle that quickly turned into horror when she delivered at 24 weeks in late 2015. At just 1 pound and 12 ounces, her son, Sutton, arrived with life-threatening health issues, including hydrocephalus - a neurological disorder caused by an abnormal buildup of cerebrospinal fluid in the brain that affects more than one million Americans.
-
NICE Irreversible Electroporation for Treating Prostate Cancer Announcement
Around half of all men say lack of sexual function is a significant problem to them after prostate cancer intervention, highlighted in an international survey from 32 countries and over 5000 men by the Europa-Uomo group1. Real world evidence is important to understand what is happening to patients in healthcare2, so AngioDynamics welcomed the news last week that the UK’s National Institute for Health and Care Excellence (NICE) Interventional Procedures Advisory Committee (IPAC) upgraded the guidance for...
-
Best HIFU ultrasound facelift machine for medical aesthetic
Today, the medical aesthetic industry has developed to make people more comfortable and safe in their pursuit of beauty. Among the many medical aesthetic procedures available, the best HIFU machine professional is a popular one. It is based on high intensity focused ultrasound technology and provides amazing aesthetic results. This article will reveal the magic of HIFU in a number of sections. Bvlaser is a ODM face lift HIFU machine manufacturer, we have HIFU vaginal tightening machine for sale. Principles of...
-
Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) QUASAR is expected to enroll around 800 patients in 27 countries Study will add to the robust development program for aflibercept 8 mg, exploring the potential to achieve visual...
Customer comments
No comments were found for JenaValve Technology Welcomes Jane Metcalf as Vice President, Regulatory Affairs and Quality. Be the first to comment!